Clinical Trial Update: Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating niraparib in combination with TSR-042 for recurrent endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Niraparib (Niraparib)
• TSR-042 (dostarlimab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Endometrial Cancer | Phase 2 | Status: UNKNOWN